NASDAQ:APMD

Apnimed Q2 2026 Earnings Results & Report

Apnimed logo
$17.38 +1.10 (+6.76%)
As of 01:40 PM Eastern

Apnimed reported Q2 2026 earnings on September 8, 2026. The company reported EPS of $0.51, while revenue was $12.08 million.

Earnings Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Apnimed EPS Results

Actual EPS
$0.51
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Apnimed Revenue Results

Actual Revenue
$12.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Apnimed Q2 2026 Earnings FAQ

Apnimed (NASDAQ:APMD) reported earnings of $0.51 per share for Q2 2026. The report was announced on Tuesday, September 8, 2026.

Apnimed reported revenue of $12.08 million for Q2 2026.

Apnimed Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
See More Apnimed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Apnimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apnimed and other key companies, straight to your email.

About Apnimed

Apnimed (NASDAQ:APMD) is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea. The company aims to offer drug-based treatment options for people who may not use or benefit from existing device-based therapies.

Its lead candidate, AD109, is an investigational oral combination of atomoxetine and aroxybutynin (oxybutynin) designed to help maintain upper-airway muscle activity during sleep. Apnimed has evaluated AD109 in clinical trials for obstructive sleep apnea; it is not an approved treatment.

Apnimed is based in Cambridge, Massachusetts. Its research and development efforts are centered on advancing pharmaceutical treatments for sleep apnea and related conditions.

View Apnimed Profile